What are the recent trends in market size and growth for the erythropoietin (epo) market?
The erythropoietin (EPO) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2024 to $19.25 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to patient education and awareness, pharmaceutical industry consolidation, healthcare reimbursement policies, market expansion and demand growth, patent expiration and biosimilar entry.
The erythropoietin (EPO) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to market competition and biosimilar impact, disease prevalence projections, healthcare policy and reimbursement changes, emerging markets growth, clinical trials and research focus. Major trends in the forecast period include supply chain management, global expansion and emerging markets, patient education and awareness, reimbursement policies, market consolidation and mergers.
Get Your Free Sample of The Global Erythropoietin (EPO) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3436&type=smp
How have varous drivers impacted the growth of the erythropoietin (epo) market?
The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the coming years. The growing cases of chronic kidney disease require erythropoietin administration, which is used to make red blood cells to improve immunity. For instance, in 2023, according to the Centers for Disease Control, a US-based federal agency, approximately 14% of U.S. adults, equating to around 35.5 million people, are estimated to have chronic kidney disease (CKD). Therefore, the rising incidence of chronic kidney diseases increases the demand for erythropoietin, thereby driving the market revenues.
What are the primary segments of the erythropoietin (epo) market?
The erythropoietin (EPO) market covered in this report is segmented –
1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products
2) By Drug Class: Biologist, Biosimilar
3) By Application: Cancer, Hematology, Renal Diseases, Neurology, Other Applications
Subsegments:
1) By Epoetin-Alfa: Epoetin-Alfa, Epoetin-Alfa Biosimilars
2) By Epoetin-Beta: Epoetin-Beta, Epoetin-Beta Biosimilars
3) By Darbepoetin-Alfa: Darbepoetin-Alfa, Darbepoetin-Alfa Biosimilars
4) By Other Products: Peginesatide, Other Novel EPO Products
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/erythropoietins-global-market-report
Which firms are leading the erythropoietin (epo) market?
Major companies operating in the erythropoietin (EPO) market include Amgen Inc., Roche Holding AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd., 3SBio Inc., Celltrion Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Reliance Life Sciences Pvt. Ltd., Biocon Limited, Chugai Pharmaceutical Co., Kyowa Kirin Co. Ltd., Apotex Inc., CJ Healthcare Corp., STADA Arzneimittel AG, Hospira Inc., Sandoz International GmbH, Torrent Pharmaceuticals Ltd., LG Life Sciences Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals.
What are the top industry trends projected to impact the erythropoietin (epo) market?
Major companies in the erythropoietin market are focusing on the introduction of oral medications that offer more convenient alternatives to traditional injectable therapies. This aims to improve patient comfort, compliance, and treatment flexibility, particularly for individuals managing chronic conditions like anemia in chronic kidney disease (CKD). For instance, in February 2023, GlaxoSmithKline (GSK), a UK-based multinational pharmaceutical and biotechnology company, launched Jesduvroq (daprodustat) tablets. This oral medication helps boost erythropoietin levels helping to manage anemia in CKD patients by keeping hemoglobin levels within a target range. The key aim of Jesduvroq is to provide a more convenient alternative to injectable therapies, improving patient comfort, compliance, and treatment flexibility for dialysis patients.
How do regional factors impact the erythropoietin (epo) market, and which region is the largest contributor?
North America was the largest region in the erythropoietin (EPO) market in 2024. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Erythropoietin (EPO) Market Report 2025 Offer?
The erythropoietin (epo) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Erythropoietin (EPO) refers to a glycoprotein hormone that naturally induces the generation of red blood cells and is produced by the kidney’s peritubular cells. Red blood cell scarcity, or anemia, is treated with it. Weakness, weariness, and shortness of breath are signs of anemia because red blood cells deliver oxygen to the tissues and organs.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3436
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
